Form 4: Amneal Pharmaceuticals Director Reports Stock Transaction
Insider Transaction (Form 4)
J Kevin Buchi, a Director of Amneal Pharmaceuticals, Inc., reported multiple transactions in common stock on September 11, 2026.
Summary
- Option exercise/conversion: acquired 20,445 Class A Common Stock at $14.45 ($295,430) on September 11, 2026; holds 95,522 after (Direct).
- Option exercise/conversion: disposed of 20,445 Stock Option on September 11, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
J Kevin Buchi — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Option exercise/conversion | Class A Common Stock | 20,445 | $14 | $295.4K | 95,522 |
| 2026-09-11 | Option exercise/conversion | Stock Option | 20,445 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Option exercise/conversion (20,445 shares) |
| 2026-09-11 | Option exercise/conversion (20,445 shares) |
Keywords
insider transaction, Form 4, AMRX, Amneal Pharmaceuticals, Inc., neutral, J Kevin Buchi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.